In liquid pharmaceuticals, the stakes could not be higher: the correct dosage and usage can literally be a matter of life and death. Marco Pelka, market manager PCE of Mettler-Toledo, explains how manufacturers and packaging companies in this field can harness product inspection to ensure they produce high quality liquid pharmaceutical products.
Key insights:
- The production of the COVID-19 vaccine has been a catalyst for change in producing more liquid pharmaceuticals directly into bottles, vials and ampules as standard packaging formats.
- Product inspection technology such as checkweighing, vision inspection and track and trace check and ensure that products are safe, complete, compliant, and traceable.
- There can be no compromise on quality standards, so product inspection solutions must be deployed to follow CGMP guidelines set by the US FDA.
As at the end of May 2022, more than 143 million COVID-19 doses had been administered in the UK since this unprecedented immunisation campaign began in 2020. Both here and worldwide, there is no doubt that the pandemic vaccination programme has done much to raise the profile of research into, and deployment of liquid pharmaceutical drugs. The liquid pharmaceutical market has been growing due to the importance of biologics and cancer drugs that are produced more effectively in liquid form.